Urol. praxi, 2014; 15(4): 159-161
Chemotherapy in urologic oncology; let us not be afraid to indicate treatment
- Onkologicko-chirurgické oddělení, FN u sv. Anny, Brno
Chemotherapy in urology is an important adjunct to locoregional procedures, i.e. surgical treatment and radiotherapy, while, in particular,
being an indispensable therapeutic method in metastatic or locally advanced tumours. Chemotherapy can extend life; when administered,
however, it has a number of adverse effects. Novel agents used in the second-line therapy for metastatic disease – cabazitaxel in
castration-resistant prostate cancer and vinflunine in urothelial carcinoma of the bladder – have become standard treatment because
of their benefit.
Keywords: chemotherapy, adverse effects, gemcitabine/cisplatin, M-VAC, cabazitaxel, vinflunine
Published: October 1, 2014 Show citation
References
- De Bono JS, Oudard S, Ozguroglu M, et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of multinational phase III trial (TROPC). J Clin Oncol [46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8,Chicago) 2010; 28(Suppl. 15): Abst 4508.
Go to original source... - Fumoleau P. Phase I and pharmacokinetic studies of RPR116258A given as a weekly 1-h infusion at day 1, day 8, Day 15 and day 22 every 5 weeks in patients with advanced solid tumors. AACR-NCI-EORTC Int Conf Mol Target Cancer Ther 2001, A282.
- Mita, AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancr Res 2009; 15(2): 723-730. Go to original source...
Go to PubMed... - Pivot X, Koralewski P, Hidalgo J, et al. A multicenter phase II study of XPR6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008; 19(9): 1547-1552. Go to original source... Go to PubMed...
- von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin with methotrexate, vinblastine, doxorubicin plus cisplatin in patient with bladder cancer. J Clin Oncol 2005; 23(21): 4602-4608. Go to original source... Go to PubMed...
- Simoens C, Vermorken JB, Korst AE, et al. Cell cycle effects of vinflunine, the most recent promisisng Vinca Alkaloid, and its interaction with radiation, in vitro. Cancer Chemother Pharmacol. 2006; 58(2): 210-218. Go to original source... Go to PubMed...
- Bennouna J, Fumoleau P, Armand JP, et al. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patient with advanced solid tumors. Ann Oncol. 2003; 14(4): 630-637. Go to original source... Go to PubMed...
- Culine S, Theodore C, De Santis M, et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer. 2006; 94(10): 1395-1401. Go to original source... Go to PubMed...
- Vaughn DJ, Srinivas S, Stadler WM, et al. Vinflunine in platinum - pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer. 2009; 115(18): 4110-4117. Go to original source... Go to PubMed...
- Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009 Sep 20; 27(27): 4454-4461. Go to original source... Go to PubMed...